Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.99 +10.6%	$1.55	$0.99 ▼ $13.50	$100.98M	2.81	1.65 million shs	4.56 million shs
PLX Protalix BioTherapeutics	$1.49 -3.2%	$2.13	$0.82 ▼ $3.10	$118.61M	-0.21	557,304 shs	500,745 shs
PULM Pulmatrix	$7.81 -2.1%	$6.84	$1.78 ▼ $10.40	$28.51M	1.45	133,750 shs	16,489 shs
THTX Theratechnologies	$2.48 -2.0%	$2.54	$1.12 ▼ $3.13	$114.03M	0.6	814,282 shs	200,990 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	+10.56%	-19.76%	+53.08%	+9.34%	-83.63%
PLX Protalix BioTherapeutics	-3.25%	-5.70%	-10.78%	-33.48%	+25.74%
PULM Pulmatrix	-2.13%	-12.15%	+27.61%	-7.68%	+311.05%
THTX Theratechnologies	-1.98%	-3.88%	-1.98%	+57.46%	+95.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.8707 of 5 stars	4.5	1.0	0.0	0.0	3.1	0.8	0.6
PLX Protalix BioTherapeutics	2.6216 of 5 stars	3.5	4.0	0.0	0.0	0.6	0.0	1.9
PULM Pulmatrix	0.4016 of 5 stars	0.0	3.0	0.0	0.0	3.3	0.0	0.0
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$20.33	921.78% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	906.71% Upside
PULM Pulmatrix	0.00	N/A	N/A	N/A
THTX Theratechnologies	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest PULM, PLX, CABA, and THTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
4/11/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/1/2025	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
4/1/2025	CABA Cabaletta Bio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
4/1/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/1/2025	CABA Cabaletta Bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $22.00
4/1/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$5.51 per share	N/A
PLX Protalix BioTherapeutics	$59.76M	1.98	$0.08 per share	17.80	$0.47 per share	3.17
PULM Pulmatrix	$1.92M	14.84	N/A	N/A	$4.93 per share	1.58
THTX Theratechnologies	$88.67M	1.29	N/A	N/A	($0.45) per share	-5.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$67.68M	-$2.54	N/A	N/A	N/A	N/A	-50.10%	-45.49%	8/6/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.81	N/A	-21.03%	-30.89%	-11.74%	N/A
PULM Pulmatrix	-$14.12M	-$3.34	N/A	∞	N/A	-96.51%	-45.97%	-30.72%	8/11/2025 (Estimated)
THTX Theratechnologies	-$23.96M	-$0.08	N/A	35.43	N/A	-3.75%	N/A	-4.31%	7/9/2025 (Estimated)

Latest PULM, PLX, CABA, and THTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/15/2025	Q1 2025	PULM Pulmatrix	N/A	-$0.50	N/A	-$0.50	N/A	N/A
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A
3/21/2025	Q4 2024	PULM Pulmatrix	N/A	-$0.54	N/A	-$0.54	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	8.11	8.11
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PULM Pulmatrix	N/A	19.40	19.40
THTX Theratechnologies	N/A	1.08	0.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
PLX Protalix BioTherapeutics	16.53%
PULM Pulmatrix	11.84%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
PLX Protalix BioTherapeutics	6.50%
PULM Pulmatrix	0.62%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	44.05 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
PULM Pulmatrix	20	3.65 million	3.63 million	Not Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

PULM, PLX, CABA, and THTX Headlines

Recent News About These Companies

Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

June 2, 2025 | marketbeat.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

Theratechnologies to further evaluate potential sale of the company

April 16, 2025 | markets.businessinsider.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | financialpost.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | globenewswire.com

Theratechnologies Engages in Exclusive Acquisition Talks

April 15, 2025 | tipranks.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | financialpost.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | businesswire.com

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

April 11, 2025 | globenewswire.com

Future Pak submits proposals to acquire Theratechnologies

April 11, 2025 | msn.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc. ...

April 11, 2025 | gurufocus.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

April 11, 2025 | businesswire.com

Theratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment Sours

April 9, 2025 | msn.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies receives FDA approval of PAS for EGRIFTA SV sBLA

April 8, 2025 | markets.businessinsider.com

3THTX : Examining the Future: Theratechnologies's Earnings Outlook

April 8, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM, PLX, CABA, and THTX Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.99 +0.19 (+10.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.96 -0.03 (-1.76%)

As of 06/13/2025 07:50 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Protalix BioTherapeutics NYSE:PLX

$1.49 -0.05 (-3.25%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.51 +0.02 (+1.34%)

As of 06/13/2025 07:51 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Pulmatrix NASDAQ:PULM

$7.81 -0.17 (-2.13%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.80 -0.01 (-0.19%)

As of 06/13/2025 04:04 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Theratechnologies NASDAQ:THTX

$2.48 -0.05 (-1.98%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.54 +0.06 (+2.42%)

As of 06/13/2025 07:33 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time